Scientists identified Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicated that loss of Mi-2β rescues the immune response to immunotherapy in vivo.
[Nature Communications]
